• Ke Yuan, Ph.D.

Young Investigator’s Research Looks at Vascular Remodeling in PAH

Ke Yuan, Ph.D., received the 2019 PHA Aldrighetti Research Award for Young Investigators, with sponsorship support provided by Actelion Pharmaceuticals, U.S. The award, one of three Pulmonary Hypertension Association (PHA) research grants awarded last year, funds Yuan’s proposal, “SDF1 signaling: A Master Regulator of Mural Cell-Dependent Vascular Remodeling in PAH.” Yuan is an associate scientific researcher and member of

Research Fellow to Study How Inflammation Contributes to PH

Rahul Kumar, Ph.D., received the 2019 PHA/ATS Research Fellowship, one of three individual Pulmonary Hypertension Association research grants awarded last year, to study inflammation and how it contributes to pulmonary hypertension (PH). This award is in collaboration with the American Thoracic Society Foundation. His funded proposal is titled “Crosstalk Between Bone Marrow Compartment and Inflamed Lungs in Hypoxic Pulmonary Hypertension.”

Oxygen Survey May Lead to Better Technology and Advocacy

A team of Johns Hopkins University (Hopkins) engineering graduate students discovered the difficulties people with lung diseases experience accessing and obtaining portable oxygen equipment while shadowing Hopkins pulmonologists in 2018. They were inspired to take action. They learned from individual patients about the impact current portable oxygen equipment has on living a normal lifestyle and now wish to learn

PHA Presents Research on PH Awareness and Diagnostic Trends

Pulmonary Hypertension Association (PHA) staff and medical leadership presented research findings and interacted with global health care professionals with an interest in pulmonary hypertension (PH) at the American Thoracic Society (ATS) International Conference this week in Dallas. Michael Gray, vice president of quality care and research, shared research findings of current trends among physicians in the U.S., focusing on

CTEPH Study Finds Higher Survival Rates Among Those Who Have Surgery

Individuals with chronic thromboembolic pulmonary hypertension (CTEPH, World Health Organization Group 4 PH) who have surgery to remove blood clots from the lungs could have a better five-year survival rate compared to those individuals who do not have surgery, according to the results of a study of 550 people with CTEPH in the U.K. CTEPH is primarily caused by

Positive Data from INSPIRE Trial Released

New data from “INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in PAH” was presented last week during the 39th International Society for Heart and Lung Transplantation Annual Meeting and Scientific Sessions in Orlando, Fla., by principal investigator Nicholas Hill, M.D., from Tufts University School of Medicine in Boston. The INSPIRE trial

Advances in Pulmonary Hypertension

Read the latest issue of Advances in Pulmonary Hypertension, PHA’s quarterly medical journal.

Latest Edition